Cargando…

Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level

The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez, Raúl, Castro, Ana, Martínez, Jessica, Rodríguez-García, Víctor, Burgués, Octavio, Tarín, Juan J., Cano, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073139/
https://www.ncbi.nlm.nih.gov/pubmed/29932437
http://dx.doi.org/10.3390/ijms19071848
_version_ 1783344125449338880
author Gómez, Raúl
Castro, Ana
Martínez, Jessica
Rodríguez-García, Víctor
Burgués, Octavio
Tarín, Juan J.
Cano, Antonio
author_facet Gómez, Raúl
Castro, Ana
Martínez, Jessica
Rodríguez-García, Víctor
Burgués, Octavio
Tarín, Juan J.
Cano, Antonio
author_sort Gómez, Raúl
collection PubMed
description The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial tumors. Immunohistochemistry was used in an endometrial cancer tissue array containing samples from 36 tumors. The amount of RANK mRNA was examined in a tissue scan cDNA array containing cDNA from 40 tumors. Normal endometrium was examined for comparison. Immunohistochemical analyses showed that RANK expression was higher in malignant than in normal endometrium (p < 0.05). RANK expression was related to histological grade (Pearson correlation index = 0.484, p < 0.001), but not to tumor stage or to age of the women. The gene expression was similar in malignant and normal endometrium. The study of RANK isoforms confirmed that the overall relative abundance of the three clearly identified transcripts was similar in normal and pathological endometrium. RANK protein expression increased from normal to malignant endometrium, and the expression level was related with tumor grade but not with stage or the age of subjects in endometrial cancer. In contrast, similar comparisons showed no change in RANK gene expression.
format Online
Article
Text
id pubmed-6073139
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60731392018-08-13 Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level Gómez, Raúl Castro, Ana Martínez, Jessica Rodríguez-García, Víctor Burgués, Octavio Tarín, Juan J. Cano, Antonio Int J Mol Sci Article The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial tumors. Immunohistochemistry was used in an endometrial cancer tissue array containing samples from 36 tumors. The amount of RANK mRNA was examined in a tissue scan cDNA array containing cDNA from 40 tumors. Normal endometrium was examined for comparison. Immunohistochemical analyses showed that RANK expression was higher in malignant than in normal endometrium (p < 0.05). RANK expression was related to histological grade (Pearson correlation index = 0.484, p < 0.001), but not to tumor stage or to age of the women. The gene expression was similar in malignant and normal endometrium. The study of RANK isoforms confirmed that the overall relative abundance of the three clearly identified transcripts was similar in normal and pathological endometrium. RANK protein expression increased from normal to malignant endometrium, and the expression level was related with tumor grade but not with stage or the age of subjects in endometrial cancer. In contrast, similar comparisons showed no change in RANK gene expression. MDPI 2018-06-22 /pmc/articles/PMC6073139/ /pubmed/29932437 http://dx.doi.org/10.3390/ijms19071848 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gómez, Raúl
Castro, Ana
Martínez, Jessica
Rodríguez-García, Víctor
Burgués, Octavio
Tarín, Juan J.
Cano, Antonio
Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
title Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
title_full Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
title_fullStr Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
title_full_unstemmed Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
title_short Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
title_sort receptor activator of nuclear factor kappa b (rank) and clinicopathological variables in endometrial cancer: a study at protein and gene level
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073139/
https://www.ncbi.nlm.nih.gov/pubmed/29932437
http://dx.doi.org/10.3390/ijms19071848
work_keys_str_mv AT gomezraul receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel
AT castroana receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel
AT martinezjessica receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel
AT rodriguezgarciavictor receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel
AT burguesoctavio receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel
AT tarinjuanj receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel
AT canoantonio receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel